Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EHC vs FMS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EHC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–2 Matrix Metrics)

EHC Overall Winner 6-Pillar Tally: EHC 4 – 2 FMS Matrix Metrics: EHC 7 – 2 FMS

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Fresenius Medical Care AG (FMS) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas FMS carries 44.7/100 (HOLD) at $20.44 (8.7x Forward P/E, 10.1% operating margin).

  • Technical & Structure Timing Caution: EHC trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8); meanwhile FMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EHC vs FMS
EHC NYSE Head-to-Head Winner
Encompass Health Corporation Common Stock
Services-Hospitals
$133.65
+1.04% 1D
Market Cap $13.0B
TTM Revenue $6.34B
Forward P/E 19.4x
Beta / 30D Vol -0.10β · 40% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 54.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $135.78 · SMA50: $128.15
FMS NYSE
Fresenius Medical Care AG
Services-Misc Health & Allied Services, Nec
$20.44
+1.54% 1D
Market Cap $10.4B
TTM Revenue $12.3B
Forward P/E 8.7x
Beta / 30D Vol 0.03β · 40% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.4%), weak momentum, RSI 37
RSI-14: 36.8 · SMA20: $22.23 · SMA50: $22.15

6-Pillar Scorecard Institutional Category Breakdown (EHC 4 – 2 FMS)

Columns: Metric · EHC · FMS
1. Valuation Multiples FMS
Forward P/E 19.4x 8.7x
Trailing P/E 21.2x 11.6x
PEG Ratio 0.41x 0.92x
EV / Revenue 2.5x 0.8x
2. Growth & Scale EHC
Revenue Growth (YoY) +8.9% +1.1%
Earnings Growth (YoY) +21.6% -35.4%
TTM Revenue (USD) $6.34B $12.3B
Market Cap $13.0B $10.4B
3. Profitability & Quality EHC
Gross Margin 44.1% 26.5%
Operating Margin 18.4% 10.1%
Net Profit Margin 10.2% 4.2%
Return on Equity (ROE) 25.1% 7.8%
4. Balance Sheet & Cash Flow FMS
Cash Generation (TTM) $457M $1.71B EBITDA
Cash Flow Margin 7.2% 13.8% EBITDA Mgn
Net Cash / Leverage $2.73B Net Debt (1.05x D/E) $27.69 Book/Sh · 7.8% ROE
Dividend Yield 0.58% 4.33%
5. Options & Positioning EHC
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 27.0% (8th %ile) 38.4% (<1st %ile)
Put/Call OI Skew 0.25x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat EHC
OpEx & R&D Intensity 25.7% of Rev ($1.63B) 16.4% of Rev ($2.02B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EHC (7) vs FMS (2)
Institutional Metric EHC FMS Criterion Row Edge
Market Capitalization
Scale
$13.0B $10.4B Larger Scale EHC
Trailing P/E Ratio
Valuation
21.2x 11.6x Lower Multiple FMS
Forward P/E Ratio
Valuation
19.4x 8.7x Lower Multiple FMS
Revenue Growth (YoY)
Growth
+8.9% +1.1% Higher Growth EHC
Operating Margin (TTM)
Profitability
18.4% 10.1% Higher Margin EHC
Net Profit Margin
Profitability
10.2% 4.2% Higher Margin EHC
Return on Equity (ROE)
Capital Efficiency
25.1% 7.8% Higher ROE EHC
52-Week Range Position
Momentum
80% ($93–$144) 7% ($20–$26) Stronger Trend EHC
Beta / 30D Volatility
Risk Regime
-0.10β · 40% Vol 0.03β · 40% Vol Lower Realized Risk Tie
Unified Institutional Score
Composite Signal
52.0 / 100 (HOLD) 44.7 / 100 (HOLD) Higher Composite EHC
Trailing 12M Revenue (USD)
Operating Scale
$6.34B $12.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
44.1% 26.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.41x PEG · 2.5x EV/Rev 0.92x PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$457M ($2.73B Net Debt (1.05x D/E)) $1.71B EBITDA ($27.69 Book/Sh · 7.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EHC +14.11 pp
EHC: +6.06% · FMS: -8.05%
3M Horizon EHC +23.66 pp
EHC: +10.53% · FMS: -13.13%
6M Horizon EHC +32.88 pp
EHC: +27.33% · FMS: -5.55%
1Y Horizon EHC +29.73 pp
EHC: +19.42% · FMS: -10.31%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EHC vs FMS. Trailing 12-month operating profitability (EHC 18.4% vs FMS 10.1%) and valuation multiples (EHC 19.4x vs FMS 8.7x Forward P/E) are benchmarked directly in Pillar 4 below.

EHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.34B
Gross Margin44.1%
Op. Margin18.4%
ROE / Fwd P/E25.1% · 19.4x
FMS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12.3B
Gross Margin26.5%
Op. Margin10.1%
ROE / Fwd P/E7.8% · 8.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EHC CONSOLIDATION
73d in phase · OBV DISTRIBUTION
Current IV 27.0%
IV Percentile 8th %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact EHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FMS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 38.4%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EHC Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $13.0B market capitalization and 18.4% operating margin.
OpEx & R&D Reinvestment 25.7% of Rev ($1.63B)
90D Engineering Disclosures 0 Published
FMS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $10.4B market capitalization and 10.1% operating margin.
OpEx & R&D Reinvestment 16.4% of Rev ($2.02B)
90D Engineering Disclosures 0 Published

Investor FAQ EHC vs FMS Key Questions & Quantitative Answers

As of Nov 20, 2026, Encompass Health Corporation (EHC) is the stronger overall head-to-head candidate over Fresenius Medical Care AG (FMS) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). EHC carries a Unified Composite Score of 52.0/100 (HOLD) at $133.65 (19.4x Forward P/E, 18.4% operating margin), whereas FMS carries 44.7/100 (HOLD) at $20.44 (8.7x Forward P/E, 10.1% operating margin). Technical & Structure Timing Caution: EHC trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8); meanwhile FMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

EHC leads the Growth & Scale pillar: EHC posts +8.9% YoY revenue growth and +21.6% YoY earnings growth on $6.34B TTM revenue (44.1% gross margin, 18.4% operating margin), compared with FMS at +1.1% YoY revenue growth and -35.4% YoY earnings growth on $12.3B TTM revenue (26.5% gross margin, 10.1% operating margin). On trailing 12-month operating scale, EHC generates $6.34B in USD-normalized revenue versus $12.3B for FMS. In operating R&D and SG&A reinvestment, EHC deploys 25.7% of Rev ($1.63B) (0 90-day corporate R&D disclosures) versus 16.4% of Rev ($2.02B) (0 disclosures) for FMS.

FMS screens cheaper on headline valuation multiples. EHC trades at 19.4x Forward P/E, 21.2x Trailing P/E, 0.41x PEG, and 2.5x EV/Revenue (7.2% FCF margin), whereas FMS trades at 8.7x Forward P/E, 11.6x Trailing P/E, 0.92x PEG, and 0.8x EV/Revenue (13.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EHC (25.1% ROE) versus FMS (7.8% ROE) capital efficiency.

In options market volatility and institutional positioning, EHC carries 27.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.10β · 40% Vol realized risk). By comparison, FMS carries 38.4% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.